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Abstract
Background: Estimates of the risk of developing Crohn’s disease (CD) can be made using DNA testing for
mutations in the NOD2 (CARD15) gene, family history, and smoking status. Smoking doubles the risk of CD, a risk
that is reduced by stopping. CD therefore serves as a timely and novel paradigm within which to assess the utility
of predictive genetic testing to motivate behaviour change to reduce the risk of disease. The aim of the study is to
describe the impact upon stopping smoking of communicating a risk of developing CD that incorporates DNA
analysis. We will test the following main hypothesis:
Smokers who are first degree relatives (FDRs) of CD probands are more likely to make smoking cessation attempts
following communication of risk estimates of developing CD that incorporate DNA analysis, compared with an
equivalent communication that does not incorporate DNA analysis.
Methods/design: A parallel groups randomised controlled trial in which smokers who are FDRs of probands with CD
are randomly allocated in families to undergo one of two types of assessment of risk for developing CD based on either:
i. DNA analysis, family history of CD and smoking status, or
ii. Family history of CD and smoking status
The primary outcome is stopping smoking for 24 hours or longer in the six months following provision of risk
information. The secondary outcomes are seven-day smoking abstinence at one week and six month follow-ups.
Randomisation of 470 smoking FDRs of CD probands, with 400 followed up (85%), provides 80% power to detect a
difference in the primary outcome of 14% between randomised arms, at the 5% significance level.
Discussion: This trial provides one of the strongest tests to date of the impact of communicating DNA-based risk
assessment on risk-reducing behaviour change. Specific issues regarding the choice of trial design are discussed.
Trial Registration: ISRCTN: ISRCTN21633644
Background
There are high expectations regarding the potential for
estimates of disease risk incorporating DNA analysis to
motivate behaviour change more strongly than other
types of risk information [1,2]. Such expectations are
consistent with theories of attitude change which predict
that the greater the personal salience of information,
such as information regarding one’so w nD N A ,t h e
greater the impact [3]. We present here a protocol for a
randomised controlled trial assessing the behavioural
impact of using DNA analysis to estimate disease risk.
This DNA analysis will be used to quantify the suscept-
ibility to Crohn’s disease (CD) of smokers who are first
degree relatives (FDRs) of probands with CD, a
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The behavioural effect of communicating the results of
the analysis will be measured by the proportion of smo-
kers who report stopping for 24 hours or longer in the
six months following the provision of the risk
assessment.
CD is a relatively common, complex genetic condition
with a population prevalence of around 1 per 1000 per
lifetime [4] and first degree relatives (FDRs) have an
approximately twenty-fold increased risk of developing
the condition [5]. Results from recent epidemiological
and genetic studies now make it possible to offer rela-
tives of probands increasingly precise information about
their chances of developing the disease, using DNA ana-
lysis of the NOD2 genotype [5,6].
Smoking is an additional risk factor and is associated
with a two-fold increase in the risk of developing CD
[7]. Smoking also leads to a more aggressive course in
those with the disease [8,9]. Importantly, this pattern is
reversed by smoking cessation [10].
As can be seen from Table 1 the relative risks for
NOD2 mutations in CD are much lower than the risks
for highly penetrant mutations in single gene disorders.
However, they are higher than most other mutations
associated with complex disorders. In those who are
NOD2 mutation-negative the lifetime absolute risk of
developing CD is very low (approximately 2% in first
degree relatives; see Lewis et al [5]). Since commercial
testing is currently being offered for a range of common,
complex disorders with the expectation of motivating
behaviour to reduce risk (e.g. 23 and Me https://
www.23andme.com/; Navigenics http://www.navigenics.
com/ predictive testing for CD serves as a timely and
novel paradigm in which to assess the impact of com-
municating the results of predictive genetic testing in
motivating risk-reducing behaviour change, in this case
smoking cessation. A series of genome-wide association
scans in CD have recently identified multiple new sus-
ceptibility genes and loci (reviewed by Mathew [11]). In
most cases, however, the associations have been
detected with single nucleotide polymorphisms (SNPs)
that tag common haplotypes at these loci. Since most of
the causal genes or causal sequence variants have not
yet been clearly defined, the precise degree of additional
genetic risk that they confer is unknown.
We are unaware of any previous attempt to provide
relatives of probands with CD with information that
might encourage them to engage in behaviours to
reduce their risks of developing the condition. Of inter-
est is whether providing precise and personalised DNA-
based information about the likelihood of developing
Crohn’s disease and how such a likelihood might be
reduced leads to smoking cessation. Two studies have
evaluated the impact of DNA-based risk information of
developing lung cancer on smokers’ motivation to stop
smoking. Both used a general population sample
[12-14]. While the first of these provided evidence of
increased motivation to stop smoking [12,13], the other
did not, with over 50% of smokers in the study failing to
understand or recall their DNA test results [14]. Neither
study found that DNA-based risk information increased
smoking cessation.
T h e r ei ss o m ee v i d e n c et os u g g e s tt h a tw h e nD N A
analyses reveal no risk-enhancing mutations there may
be higher levels of false reassurance and hence lower
rates of risk-reducing behaviour than similar levels of
risk estimated without DNA analyses [15,16]. Such an
effect may follow from presenting the results of the ana-
lysis of a risk factor that is personally salient and per-
ceived as categorical i.e. the mutation is either present
or it is not, although the risk it confers is most often
probabilistic. We therefore predict that those whose risk
analysis includes DNA but for whom no risk-enhancing
m u t a t i o n sa r ef o u n dw i l lb el e s sl i k e l yt om a k eaq u i t
attempt than those whose risk analysis did not include
DNA analysis. Additionally, we predict a dose-response
effect of the receipt of DNA-based risk information:
individuals who are revealed to have one or more risk-
enhancing mutations will be more motivated to change
their behaviour than those who receive a DNA-based
risk revealing no mutations, or those in the comparison
arm who did not undergo DNA analysis.
Objective and hypotheses
The trial objective is to estimate the impact upon stop-
ping smoking of communicating a risk of CD that
Table 1 Estimated frequencies of NOD2 genotypes in probands and FDRs, and estimated FDRs’ probability of
developing CD
NOD2 mutation
negative
NOD2 mutation
heterozygous
NOD2 mutation
homozygous
Frequency of NOD2 genotype in CD probands 65% 27% 8%
Frequency of NOD2 genotype among FDRs 75% 22% 3%
Frequency of NOD2 genotype in controls 87% 12% 1%
Risk to FDRs of developing CD conferred by
genotype
2% 4% 15%
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be examined are as follows:
Hypothesis I (Main hypothesis)
Smokers who are FDRs of CD probands are more likely
to make smoking cessation attempts following commu-
nication of risk estimates of developing CD that incor-
porate DNA analysis, compared with an equivalent
communication that does not incorporate DNA analysis
(between arm comparison).
Hypothesis II
Among smokers whose CD risk assessment includes feed-
back of DNA analysis, smoking cessation attempts are
more likely when the analysis reveals one or more risk
increasing mutations,whencompared with (a) those under-
going a similar DNA analysis that does not reveal any risk
increasing mutations (any versus no mutation; within DNA
arm comparison), (b) risk assessment that does not incor-
porate DNA analysis (any mutation versus non-DNAarm).
Hypothesis III
Among smokers whose CD risk assessment includes
feedback of DNA analysis, smoking cessation attempts
are less likely when the analysis does not reveal any risk
increasing mutations, when compared with smokers
receiving a risk assessment that does not incorporate
DNA analysis (no mutation versus non-DNA arm).
Methods/Design
Trial design (see Figure 1)
A parallel group cluster randomised controlled trial in
which smokers who are first degree relatives of pro-
bands with Crohn’s disease will receive the results of
one of two types of risk assessment for developing
Crohn’s disease, based on:
i. DNA testing for NOD2 genotype, family history of
CD and smoking status, or,
ii. family history of CD and smoking status
Participants
Participants will comprise 470 FDRs of probands with
CD, aged 18 years and over, who do not have a diagno-
sis of CD or ulcerative colitis and who smoke five or
more cigarettes daily. Participants must be able to give
informed consent and to complete, either alone or with
assistance, the study questionnaires.
Exclusion criteria:
1. Cigar, pipe and oral tobacco users who do not also
smoke five or more cigarettes daily.
2. Those currently taking medication for smoking ces-
sation or medication with a known influence on smok-
ing cessation that they cannot stop (e.g. nortriptyline for
depression).
3. Those who are non-English speakers.
Interventions
The components of the interventions described below
are shown in Table 2.
Communication of risk assessment for Crohn’s disease
All participants will receive a booklet outlining the
results of their risk assessment of developing CD. This
comprises presentation of three lifetime risk figures:
population risk (1:1000); personal risk, presented
numerically with a denominator of 1000 and accompa-
nied by a visual display [17]; and personal risk following
smoking cessation. The booklet includes explanations of
how the risk figure was estimated and of how stopping
smoking reduces the risk of CD. The nature of the
risk assessment differs by arm and risk estimates are
calculated as follows:
Comparison (non-DNA) arm
Personal risks of developing CD are based on residual
familial risk i.e. whether the proband is a parent, sibling
or child (estimating the effect of unidentified genes,
after accounting for the contribution of NOD2); and
smoking status (two-fold increased risk for smokers), as
described in previous research [5].
Intervention (DNA) arm
Personal risks of developing CD are again based on
residual familial risk and smoking status, plus NOD2
genotype (conferring a gene dosage effect on risk)
derived from a mouthwash sample returned by the
participant, again calculated according to prior
research [5]. In effect, the risk communicated to the
DNA arm is calibrated into high, medium and low,
whilst the control arm receive an “averaged” genetic
risk, based on their family history. DNA will be
extracted and analysed for known NOD2 (also known
as CARD15) susceptibility mutations (see Procedure for
more details).
Brief smoking cessation advice
Receipt of the results booklet is followed by a telephone
call (see “Telephone call 2” in Procedure) from a
research counsellor trained as an NHS Stop Smoking
Service provider who goes over the information in the
booklet to ensure comprehension and to deliver a brief
smoking cessation intervention. This is aimed at increas-
ing motivation to stop smoking and in those motivated
to stop, to encourage use of the NHS Stop Smoking
Services.
Procedure
Participant recruitment
First degree relatives of people affected by Crohn’sd i s -
ease will be identified via three routes:
i. Probands receiving care through hospital services.
Proband addresses will be obtained by gaining
accesses to CD proband databases at participating
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tal Trust Research and Development department.
Probands may be given study invitation packs or
telephoned by members of the clinical team.
ii. Probands who are members of the National Associa-
tion for Colitis and Crohn’s Disease (NACC). All mem-
bers who have CD will be posted an invitation pack.
iii. Advertising in the newsletters of NACC and the
charity Ostomy Lifestyle.
Probands will be posted a study information booklet
and consent form. They will be asked to inform any
FDRs of theirs who smoke and who are unaffected by
CD or ulcerative colitis about the study. They will be
asked to indicate on the consent form their preferred
method for the study team to contact their relatives,
either requesting the study information from the research
team in order to give this to their relatives themselves, or
providing their relatives’ contact details, for the research
team to make the contact. This procedure was developed
as part of a feasibility study for this trial [18].
Information booklets and consent forms will be dis-
tributed to identified FDRs. Eligible FDRs who have
read and understood the study information booklet will
sign and return the consent form to the research team
at KCL. The research counsellor will then telephone the
participant and obtain further verbal consent before
entering them into the trial.
Telephone call 1
Information will be collected about the participant’s
family history of CD to contribute to the risk assess-
ment, as well as demographic and smoking characteris-
tics. The participant’s date of birth will be noted for
randomisation at a later date.
Participants will be randomised after Telephone call 1.
Those randomised to the DNA arm will be asked to pro-
vide a saliva sample for a DNA test. Non-DNA arm parti-
cipants will not undergo a DNA test and hence will not be
asked to provide a saliva sample. The trial co-ordinator
will then send the results booklet to the participant (see
Communication of risk assessment for Crohn’s disease).
Telephone call 2
Following receipt of the results booklet, the research
counsellor will telephone the participant to administer
the brief smoking cessation intervention as previously
described.
Telephone call 3
A member of the research team who did not deliver the
intervention will assess self-reported seven-day smoking
cessation approximately one week after telephone call 2
has taken place.
Telephone call 4
This will take place six months after the second tele-
phone call to assess the primary endpoint, seven-day
smoking cessation, and levels of worry caused by the
risk assessment. This telephone call will be made by a
member of the research team who did not deliver the
intervention and who is blind to allocation. Saliva sam-
ples will be collected via post in those who report seven
day smoking abstinence, to allow cotinine validation.
DNA testing
DNA will be extracted and analysed for the three known
NOD2 susceptibility mutations: R702W, G908R and
1007fs by allele-specific PCR amplification [19]. Assays
Figure 1 Trial design.
Table 2 Intervention components present in DNA and non-DNA risk assessment arms
Intervention component DNA arm Non-DNA arm
Mouthwash posted to participant to collect saliva sample for NOD2 Genotyping √ X
Booklet containing results of risk assessment posted approximately 6 weeks after initial contact √√
Personal risk presented using a numerical risk with a denominator of 1000, accompanied by a visual display √√
Feedback of risk assessment based on family history of CD and smoking Status √√
Feedback of risk assessment based on NOD2 genotype √ X
Explanation of NOD2 gene in booklet √ X
Explanation of how stopping smoking reduces the risk of CD in booklet √√
Smoking cessation advice over the telephone √√
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known NOD2 genotypes derived by DNA sequencing in
each genotyping experiment. A greater than 95% success
rate is expected for the extraction and amplification of
DNA. In the event that DNA is not collected or the
PCR procedure fails, the participant will be asked to
provide a further sample. While the prevalence of
NOD2 mutations is lower or zero in populations not of
European ancestry, the penetrance of the gene is not
known to vary by ethnicity.
Outcomes
Primary outcome
The primary outcome, assessed six months after the
intervention, is making one or more quit attempts of
24 hours or longer in the six months following assess-
ment of CD risk. This end point is a reliable predictor
of eventual cessation [20].
Secondary cessation outcomes
Seven-day smoking cessation at one week Self-reported
smoking cessation will be assessed at one week follow-
ing receipt of the CD risk assessment.
Seven-day smoking cessation at six months At six
months abstinence from smoking in the preceding seven
days will be assessed using the Russell standard proce-
dures [21], counting participants lost to follow up as
being smokers, and self-reported smoking status will be
verified biochemically. Validated abstinence requires
smoking no more than 5 cigarettes in the prior seven-
day period and a cotinine level of <15 ng/ml.
Additional outcomes Questionnaires administered
within telephone calls 1,3 and 4 will assess key variables
derived from three psychological theories, specifically
Leventhal’s self-regulation model of health and illness
[22], Protection Motivation Theory [23], and the Theory
of Planned Behaviour [24]. We will also assess self-
reported smoking-related behaviours (such as use of
NRT) and participants’ recall and comprehension of
their risk assessment.
Sample size
(a) Hypothesis I
The initial sample size estimate comprised 540 smokers
who were FDRs of probands with Crohn’sd i s e a s e .2 7 0
would be cluster randomised by family to DNA testing
and 270 to the non-DNA arm. Allowing for 20% drop-
out we expected to follow-up 215 per arm. With this
sample size, and allowing for clustering, there was 80%
power to detect an odds ratio (OR) of 1.75 for likelihood
of engaging in a quit attempt between randomised arms
using a two-sided test at the 5% level of significance. In
a general population sample without presentation of risk
information 29% reported a quit attempt by six-month
recall [25]. On this basis we have estimated that the
proportion reporting having made one or more quit
attempts of 24 hours or more in the preceding six
months would be 35% in the non-DNA arm, enabling
detection of 49% or higher in the DNA testing interven-
tion arm (OR = 1.75). In order to allow for clustering
effects by family the sample size was increased by a
design effect of 8%. This was based on a mean cluster
size of 1.13 from the pilot study [18] and an allowance
that the intracluster correlation (ICC) could be as high
as 0.6 based on observing a range of ICCs between 0.3
and 0.87 for behavioural outcomes clustered at the
household level [26].
To check the assumptions underlying the sample size
calculation, an interim analysis including the first 266
(50%) participants was conducted. This revealed a higher
completion rate (87%), confirmed the cluster size (mean
cluster size 1.14) and identified the ICC to be zero. The
trial steering committee supported a revised sample size
calculation based on a follow-up rate of 85% and with-
out the need to account for clustering in the analysis.
This meant that without loss of power for primary
or secondary outcomes we could follow up 200 per
arm, requiring recruitment of only 470 randomised
participants.
(b) Hypotheses II and III
Amongst the 200 followed-up in the DNA analysis arm
it is expected that 44 will be heterozygous for NOD2,
six homozygous, and 150 mutation negative. The follow-
ing sets of secondary comparisons will be made to test
Hypotheses II and III:
II(a) Within DNA arm: 0 mutations vs. 1 or 2
mutations
II(b) Between non-DNA arm and a subgroup of DNA
arm (1 or 2 mutations)
III Between non-DNA arm and a subgroup of DNA
arm (0 mutations)
The odds ratios that can be detected with 80% power
with the above group sizes at the 5% level of significance
are as follows:
II(a): An average odds ratio of 2.5 within DNA arm
b o t hi nt h ea b s e n c eo fa n yd i f f e r e n c eb e t w e e nt h er a n -
domised groups (29% in 0 mutations group versus 52%
in 1 or 2 mutations group; group average 35%; detect-
able OR = 2.55) and in the presence of a difference
between the randomised groups (43% in 0 mutations
group versus 65% in 1 or 2 mutations group; group
average 49%; detectable OR = 2.45).
II(b): There is 80% power to detect an odds ratio of
2.5 between the non-DNA arm and those with 1 or 2
mutations in the DNA arm (35% in the non-DNA arm
versus 57% in the 1 or 2 mutations group of the DNA
arm; detectable OR = 2.45).
III: There is 80% power to detect an odds ratio of 0.5
between the non-DNA arm and those with 0 mutations
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in the 1 or 2 mutations group of the DNA arm; detect-
able OR = 0.50).
Randomisation
(a) Procedure
The research counsellor (KCL) will enroll each partici-
pant into the trial and the trial coordination team (KCL)
will send each participant’s data for randomisation to
the statistical team (Cambridge), and receive back the
allocated group.
(b) Method
Each participant will be cluster randomised by family to
one of the two arms, with allocation on a 1:1 basis. The
allocation method will be blocked randomisation with
the randomisation sequence prepared by the trial
statistician.
(c) Concealment
The randomisation sequence will be concealed from the
trial co-ordination team and research counsellor and the
statistical team will only be given study identification
data necessary for randomisation. Participant date of
birth will be required at study closure to confirm agree-
ment between the generated sequence and that used in
the trial. After assignment of a participant, neither the
research counsellor nor the participant will be blind to
the participant’s study arm.
Research governance
COREC approval has been given (REC: Hertfordshire 1:
06/Q0201/19, 26
th June, 2006).
R&D approval has been obtained from the hospitals
(42 NHS Trusts across the UK) through which the pro-
bands will be contacted, and from the South London
and Maudsley Trust, the employer of the research
counsellors.
Fidelity checks
All telephone calls will be tape-recorded. A sub-sample
of these recordings will be randomly selected and tran-
scribed to assess fidelity to the clinical protocol. The
tapes will be stored in a locked cabinet and a sample
analyzed on a regular basis.
Adverse events monitoring
All comments made by participants and health care pro-
fessionals will be logged in the Trial Log File. They will
be given an individual number and also logged on a
computer database. Any follow-up or further action
needed will also be logged. No personal information will
be included unless absolutely necessary. The file will be
stored in a locked office.
Any incident considered serious is to be entered in the
Adverse Incident Log. This is a hardbound book that will
also be stored in a locked office. A judgement about the
incident’s severity will be made between the Principal
Investigator and the research team. Any incident
included here will have a sheet in the Trial Log File and
will also be logged on a computer database. Any follow-
up or further action will be included in the book, along-
side details regarding how the incident was resolved. No
personal information will be included unless absolutely
necessary.
An example of how adverse events monitoring could
take place is as follows:
If a participant becomes anxious after learning of their
risk of developing CD, the PI and research team will be
informed and the incident logged. An appropriate pro-
cedure will then be initiated. Depending upon the nat-
ure of the anxiety, the participant will be encouraged to
visit their GP or will be offered an appointment with of
the trial’s gastroenterology consultants. The outcome of
this contact will be monitored and logged and the parti-
cipant’s GP informed, if consent is given for this.
A n yi n c i d e n tj u d g e dt ob es e v e r eb yt h eP r i n c i p a l
Investigator and the research team will be reported
to the Data Monitoring and Ethics Committee within
24 hours.
Statistical analysis
The analysis of the primary outcome, the proportion of
participants reporting having made one or more quit
attempts of 24 hours or more in the preceding six
months, and the secondary cessation outcomes will be
compared between arms by estimating a difference in
proportions between arms together with a 95% confi-
dence interval, and the p-value from the associated chi-
squared test. The odds ratio and 95% confidence interval
will also be reported. Analyses will be on an intention to
treat basis with the common assumption for secondary
cessation outcomes that all participants are classified as
smokers except for those biochemically verified as non-
smokers. However, for the primary outcome, those miss-
ing this outcome will primarily be treated as missing
from the analysis. Missing status will be compared
between groups, and the primary difference in propor-
tions will be re-assessed assuming that missing data is
imputed as no quit attempt. All tests will be two-sided
and assessed at the 5% significance level. Sensitivity ana-
lyses will be performed to confirm that clustering makes
negligible difference to results and no difference to con-
clusions or interpretations, using Donner’s Method [27].
Hypotheses II and III will be assessed by comparing the
primary outcome between mutation status subgroups of
the DNA arm with each other and with the control
arm. To strengthen the interpretation of these non-
randomised comparisons, sensitivity analysis will be
undertaken to vary the degree to which mutation status
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analysis plan to be prepared prior to analysis.
Design considerations
We considered a design in which saliva samples are
taken in both trial arms. The potential advantage of
this design is that it increases the similarity between
trial arms for procedures of no pure experimental
interest and allows the distribution of genotypes in
each arm to be assessed in order to allow adjustment
for any imbalance in the analysis. The potential disad-
vantage of such a design is that the taking of a saliva
sample in those whose DNA is not being used to esti-
mate their risk of CD may lead to a sense of having
lost out on randomisation, and that taking a sample for
analysis can thus be seen as an integral part of the
DNA assessment and communication intervention as
applied in practice. We judged this disadvantage to out-
weigh the benefits of such a design and thus rejected it
for use in the trial.
Trial details
Registration: ISRCTN21633644
Date trial started: April 2007
Expected end date: September 2010
Expected reporting date: February 2011
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